Samsung Biologics May Add Manufacturing Capacity at its Site in Korea

Goodwin
Contact

Goodwin

Samsung Biologics has announced that it may expand its manufacturing capacity at its site in Songdo, Incheon.  Launched in 2011, Samsung has three plants housing a total of 364,000 L of mostly stainless-steel bioreactor capacity that, according to Samsung’s CEO, will be fully utilized to capacity by 2022. Samsung’s CEO had previously said that “the company will prepare to add a fourth plant and new bio campus” to keep up with the momentum of biomanufacturing demand, and that the “addition of a fourth plant is a plan that is to be studied in the long run.”  According to the Nikkei Asian Review, Samsung closed over $1.5 billion worth of orders in the past three months, including a mix of biosimilar and novel antibodies.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.